NOBEX REPORTS ORAL INSULIN CLINICAL TRIAL PROMISING.
NOBEX, Research Triangle Park, NC, a drug development company
specializing in medicinal chemistry-based drug delivery, has reported
promising results of an exploratory clinical trial for oral . . .
ELIXIR LICENSES PATENT ON HUMAN LONGEVITY CHROMOSOME.
U.S. Patent number 6,673,546 (the '546 patent) entitled
"Genetic Loci Indicative of Propensity for Longevity and Methods
for Identifying Propensity for Age-Related Disease," has been
awarded to . . .
NORTHFIELD LABS CLEARED FOR PATIENT ENROLLMENT IN PHASE
III.
Northfield Laboratories Inc., Evanston, Ill., (NASDAQ: NFLD) has
received clearance to begin patient enrollment in its pivotal Phase III
urban ambulance trial with PolyHeme(r), the . . .
BIOMARIN ACCELERATES DEVELOPMENT OF PHENOPTIN FOR PKU.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif., has
initiated clinical trials with Phenoptin(TM), an enzyme cofactor that is
a second-generation, proprietary oral form of . . .
ADAPTIVE MUTATION IS COMMON IN E.COLI.
The quickening of genetic mutation rates in bacteria may not only
happen when the microorganisms find themselves in strange and stressful
circumstances. A new report in Molecular Microbiology by . . .
ISIS 104838 GETS PROMISING DATA FROM PHASE 2 CLINICAL
TRIAL.
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), Carlsbad, Calif., has
reported data from a Phase 2 clinical trial which demonstrate that ISIS
104838, an antisense TNF-alpha inhibitor, produced a . . .
ALNYLAM LICENSES INTELLECTUAL PROPERTY FROM COLD SPRING
HARBOR.
Alnylam Pharmaceuticals, Inc., Cambridge, Mass., a leading RNAi
therapeutics company, has signed a licensing agreement with Cold Spring
Harbor Laboratory for intellectual property related to the . . .
DISCOVERY LABS INITIATES PHASE 1B ASTHMA CLINICAL TRIAL.
Discovery Laboratories, Inc. (Nasdaq: DSCO), Doylestown, Pa., a
biopharmaceutical company developing its proprietary surfactant
technology as Surfactant Replacement Therapies for respiratory . . .
PATENT ISSUED PROTECTING INTERLEUKIN-9 VACCINE
TECHNOLOGY.
Genaera Corporation (NASDAQ:GENR), Plymouth, Pa., has announced
issuance by the United States Patent and Trademark Office of patent
number 6,645,486 covering claims for reducing the activity . . .
CERUS INITIATES PHASE IB CLINICAL TRIAL FOR ACIT.
Cerus Corporation (Nasdaq:CERS), Corcord, Calif., has initiated a
Phase IB clinical trial for its allogeneic cellular immune therapy
(ACIT). The company's ACIT is being developed to improve stem . . .
PARTNERSHIPS TO INTRODUCE MINI-CHROMOSOMES INTO CANOLA.
Chromatin Inc. Chicago, has entered into partners with the National
Research Council Canada Plant Biotechnology Institute (NRC-PBI) and
Cibus Genetics of San Diego, California, to generate canola . . .
NOVARTIS TO DISTRIBUTE VENTERINARY SUTURE LINE IN U.S.
Novartis AnimalHealth US, Inc. and ETHICON Products have signed an
exclusive distribution agreement that gives Novartis US marketing rights
to the ETHICON Products premium line of sutures and . . .
FAVRILLE COMPLETES PHASE II NON-HODGKIN'S
ENROLLMENT.
Favrille, Inc., San Diego, Calif., has completed enrollment for its
current Phase II clinical trial (FavId-04) with the company's lead
investigational agent, FavId(tm). This agent is under . . .
LEVAQUIN GETS FDA APPROVAL FOR 5-DAY TREATMENT OF CAP.
The U.S. Food and Drug Administration has approved a new 5-day
dosage form of LEVAQUIN(R) (levofloxacin) Tablets/Injection and
LEVAQUIN(R) (levofloxacin in 5% dextrose) Injection 750mg . . .
LOCUS LICENSES GP41 CRYSTAL STRUCTURE FROM CORNELL
RESEARCH.
Locus Pharmaceuticals, Inc., Blue Bell, Pa., a privately held
pharmaceutical company focused on developing novel, small molecule
therapeutics, has licensed from Cornell Research Foundation . . .
MAXIM DISCOVERS POTENTIAL THERAPEUTIC FOR SARS.
Maxim Pharmaceuticals (Nasdaq: MAXM) (SSE: MAXM), San Diego, has
discovered a series of small molecules as inhibitors of the SARS
coronavirus (SARS-CoV). These compounds, designated the MX128533 . . .
ANIKA SIGNS MULTI-YEAR LICENSE/SUPPLY PACT WITH ORTHO
BIOTECH.
Anika Therapeutics, Inc. (Nasdaq:ANIK), Woburn, Mass., has signed
an exclusive, multi-year U.S. licensing and supply agreement with Ortho
Biotech Products, L.P. for Anika's ORTHOVISC(R), a highly . . .
VIACELL/AMGEN SIGN COLLABORATION/LICENSE PACT.
ViaCell, Inc. Boston, has signed a collaboration and license
agreement with Amgen Inc. in the field of cellular therapy that provides
ViaCell with licenses to certain cellular growth factors and . . .
NUCRYST INITIATES PHASE 2 CLINICAL TRIAL OF ECZEMA DRUG.
NUCRYST Pharmaceuticals Corp., Wakefield, Mass. a subsidiary of The
Westaim Corporation, has begun its first Phase 2 human clinical trial of
a topical cream formulation of its nanocrystalline . . .
GUAVA VIACOUNT FLEX ALLOWS NON-MAMMALIAN CELL
COUNT/ASSESSMENT.
With the Guava ViaCount Flex assay reagent, quick and reproducible
absolute cell count and viability assessments can now be done with
insect and other non-mammalian cells, announced Guava . . .
|
|